振東製藥(300158.SZ):控股股東約定購回式證券交易違約處置
格隆匯11月3日丨振東製藥(300158.SZ)公佈,2019年11月4日,公司控股股東振東集團將其持有的振東製藥無限售條件流通股2060萬股進行約定購回式證券交易,交易股份佔當時公司總股本的1.99%(佔最新總股本的2.00%),到期購回日為2020年11月3日。截至2020年11月3日收盤,振東集團未進行回購操作並構成違約。
近日,公司收到振東集團通知,債權人證券公司將通過集中競價交易方式和大宗交易方式對相關股份進行違約處置。
自本公告披露之日起,證券公司違約處置申報材料齊備後,深交所將根據處置申請通知中國結算深圳分公司將標的證券劃轉至證券公司用於處置的自營賬户。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.